← Back to articles

SAFE Document Review: Key Terms Every Founder Should Negotiate

When you're raising a seed round, SAFEs (Simple Agreements for Future Equity) often represent your first formal fundraising document. Many founders treat them as boilerplate—a necessary formality to get capital into the bank account. This perspective can cost you hundreds of thousands in equity and founder control. The SAFE terms you accept today directly shape your cap table, voting power, and future dilution.

Understanding the SAFE Framework

A SAFE is a convertible security designed to be faster and cheaper than traditional financing rounds. Rather than immediately determining a valuation (which can be contentious in early stages), SAFEs allow investors to put money in with the understanding that their investment converts to equity later—typically at a Series A or other qualifying event.

Think of a SAFE as a placeholder. It's not technically a stock, not technically debt, but rather a contract that says: "You're putting money in now, and we'll figure out the ownership percentage when we raise a priced round or hit a triggering event." This structure was popularized by Y Combinator to simplify early-stage fundraising, and it's become the default for seed investors.

The Valuation Cap: Your First Critical Negotiation

The valuation cap is the most important number in a SAFE. It sets a maximum valuation at which your investor's money converts to equity. Here's why this matters: if you have a $2 million valuation cap and you raise a Series A at a $10 million valuation, your seed investor converts at the lower $2 million valuation—getting significantly more equity than they would have at $10 million.

For your first SAFE, a reasonable cap depends on your stage. Pre-revenue, pre-product companies typically use $1.5M–$3M caps. Companies with meaningful traction might justify $5M–$8M. The key is this: the lower the cap, the better for your investor. The higher the cap, the better for you. You want a cap that's credible based on your stage but not so low that you're giving away excessive equity.

Don't accept the first cap offered. Many investors will start high; founders have room to negotiate down. If an investor refuses to move on valuation cap, that's data about how they view your stage and negotiating power.

The Discount Rate: Rewarding Your Seed Investors

Many SAFEs also include a discount rate—typically 10–30%—that applies when your SAFE converts. This means if your Series A prices shares at $1, your seed investors get shares at a discount (e.g., $0.80). This is a reward for taking early risk.

The discount and cap serve similar purposes, but they apply differently. If both are present, whichever benefits the investor more during conversion actually applies. So a 20% discount on a Series A might mean your seed investor pays 80% of the new round's price, or they might convert at your valuation cap—whichever is lower for them (better for them).

Negotiate the discount down. Standard ranges are 10–20%; anything above 25% is aggressive. If you have strong investor interest, use that to lower the discount. Some excellent investors will accept 10% or even no discount if the valuation cap is reasonable.

Pro Rata Rights: Controlling Future Dilution

Pro rata rights allow your investor to participate in future rounds to maintain their ownership percentage. If an investor owns 5% of your company and you raise a Series A, pro rata rights let them invest in the Series A to stay at 5% (if they choose).

This sounds neutral—just protecting their ownership. But pro rata rights have real consequences. They create pressure on you to include your seed investors in every round. If they exercise pro rata in a Series B, you're committing capital space to them. If they decline, there may be awkward conversations. And if an investor can't fund their pro rata, you may face cap table complexity.

Many founders accept unlimited pro rata rights without thinking. Smart move: cap pro rata rights. Offer pro rata only for the next round (Series A), or for two rounds maximum. This protects your investor's major upside moments while giving you flexibility in future funding rounds.

Most Favored Nation (MFN) Clauses: The Quiet Dilution Risk

An MFN clause states that if you offer future investors better terms (lower cap, higher discount), earlier investors automatically get those better terms too. This sounds protective for early investors, but it creates hidden risks for you.

Example: You raise a SAFE at a $3M cap with no MFN. You then raise another SAFE at a $2M cap (because your progress justifies it). Without MFN, both cohorts have their respective terms. With MFN on the first SAFE, the first investor drops to a $2M cap too—unexpected equity dilution from your perspective.

The standard approach: include MFN for the next funding round only (usually Series A), not for future SAFEs. This protects seed investors from you dramatically improving terms mid-seed round while allowing you to move terms over time as your company matures.

Conversion Triggers: When Equity Actually Happens

SAFEs convert to equity when specific events occur. The most common trigger is a "priced round" (Series A or beyond). Other triggers include a change of control (acquisition), early exercise events, or expiration (typically 7 years).

You want explicit clarity here. If you're acquired before a Series A, what happens to SAFEs? Standard practice: SAFEs convert at a reasonable valuation if you have one, or at a discount to the acquisition price if you don't. Some investors push for immediate conversion at the cap—negotiate against this, as it could eliminate your equity at a favorable exit.

For expiration, 7 years is standard. After 7 years, if no qualifying event occurred, the SAFE expires (investor gets their capital back, typically). This is fair—it forces resolution and doesn't leave dead capital on the cap table forever.

The Post-Money SAFE Consideration

Most SAFEs are "post-money" meaning the investor's capital is included in the valuation cap calculation. This is now standard and founder-friendly compared to older pre-money SAFEs. Ensure any SAFE you sign is explicitly post-money.

Post-money is important because it simplifies dilution math. If you raise $1M on a post-money $4M cap, the investor owns 20% ($1M / $5M including their capital). It's clearer and more predictable than pre-money calculations.

Investor Rights and Information Access

Some investors try to bundle SAFE agreements with investor rights docs that give them board observation, information rights, or other governance powers. SAFEs themselves don't typically grant these—but some investors add rider documents.

Negotiate here. Early-stage companies shouldn't give multiple seed investors board seats or heavy governance rights. Information rights (quarterly updates) are reasonable. Board observation can be reasonable for lead investors. Board seats should be reserved for priced rounds and later stages.

Multiple SAFE Trenches and Sequencing

If you're raising SAFEs from multiple investors, consider whether they're all on the same terms or if different investors get different caps/discounts. Standard practice: all seed investors (or at least all in a cohort) get the same terms. This reduces tension on your cap table and simplifies conversations.

If you're raising multiple SAFEs over time and improving terms each tranche, communicate this to earlier investors. Some will expect MFN; others won't mind. Being transparent avoids surprises and relationship damage.

Key Takeaways

• Valuation cap is critical: It determines how much equity seed investors receive. Negotiate based on your stage and traction.
• Discount rates should be 10–20%: Higher discounts are aggressive; lower discounts signal investor confidence in your trajectory.
• Limit pro rata rights: Allow pro rata for the next round or two, not unlimited future rounds. This protects investor upside while preserving your flexibility.
• Cap MFN clauses: Use MFN for the next round only, preventing mid-seed-round surprises from improved terms offered to other investors.
• Clarify conversion triggers: Explicitly state what happens if you're acquired or have other triggering events before a priced round.
• Use post-money SAFEs: Ensure every SAFE is post-money to simplify dilution calculations and cap table management.
• Restrict investor governance rights: SAFEs don't grant board seats; keep board membership for later rounds when investors have priced ownership.

Common Negotiation Mistakes Founders Make

Many first-time founders accept the first SAFE draft without negotiation, assuming "everyone uses the same terms." This is false. Experienced founders negotiate every SAFE. A 1–2% shift in cap table ownership at the seed stage compounds to massive differences by exit.

Another mistake: accepting unlimited pro rata without understanding the future burden. You're essentially promising every seed investor a seat at your Series A, Series B, and beyond—which may not be feasible if you have ten seed investors.

Finally, some founders sign SAFEs without understanding that the terms you accept now affect future pricing power. If you accept a $2M cap with 20% discounts and aggressive pro rata, Series A investors will factor that seed dilution into their valuation. Clean seed terms lead to cleaner future rounds.

When to Use SAFE vs. Other Instruments

SAFEs work best for non-lead investors in seed rounds, and for founders who want speed over certainty. If you need certainty (you want to know exactly what equity you're giving up), a priced note might be better. If you're raising from experienced VCs who expect governance rights, a Series Seed might be more appropriate.

For most early-stage founders raising seed checks under $250K per investor, SAFEs are appropriate. For larger checks or when you have a lead investor orchestrating the round, consider whether convertible notes or a Series Seed vehicle might provide clearer alignment.

FAQ: SAFE Document Review

Q: Can I change SAFE terms with different investors?
A: Yes, but be thoughtful. Standard practice is uniform terms within a cohort (e.g., all seed investors get the same cap/discount). If you're improving terms over time, expect early investors to invoke MFN or to feel short-changed. Transparency helps; surprise cap reductions damage relationships.

Q: What's a reasonable valuation cap for a pre-revenue startup?
A: Depends on your team and traction, but typically $2M–$5M for bootstrapped teams with no product. With a working prototype or early user traction, $5M–$10M is defensible. Anything over $10M for pre-revenue requires compelling story (famous founders, large market, team track record).

Q: Should I include a discount rate if I have a strong valuation cap?
A: Not necessary. A low valuation cap is often enough to compensate seed investors. If you're confident in your cap, offering a discount can be overkill. Experienced investors may accept a strong cap with no discount to close a deal faster.

Q: What happens if I don't hit a priced round for five years?
A: Your SAFE will eventually expire (typically at 7 years). The investor gets their capital back. Before expiration, you could trigger a conversion via acquisition, secondary sale, or negotiated conversion at a valuation you both agree on. A 5-year delay without traction is a problem bigger than SAFE mechanics, though.

Q: Can an investor push me to convert a SAFE before a priced round?
A: Not without your agreement. SAFEs convert on specific triggering events; early conversion requires mutual consent. Some SAFEs allow for conversion at investor election if you have major revenue; read your terms carefully.